deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02395666

Preventative Trial of Difluoromethylornithine (DFMO) in High Risk Patients With Neuroblastoma That is in Remission

A Phase II Preventative Trial of DFMO (Eflornithine HCl) as a Single Agent in Patients With High Risk Neuroblastoma in Remission

Sponsor: Beat NB Cancer Foundation

Conditions Neuroblastoma
Interventions DFMO
Updated 24 times since 2017 Last updated: Aug 2, 2024 Started: Mar 5, 2015 Primary completion: Mar 27, 2018 Completion: Aug 24, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Neuroblastoma, this trial is completed. The trial is conducted by Beat NB Cancer Foundation and has accumulated 24 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2018 · 13 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Aug 2019 · 12 months · monthly snapshot~Aug 2019 – ~May 2020 · 9 months · monthly snapshot~May 2020 – ~Dec 2020 · 7 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Jan 2022 · 3 months · monthly snapshot~Jan 2022 – ~May 2022 · 4 months · monthly snapshot~May 2022 – ~Jan 2023 · 8 months · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Mar 2023 · 28 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jul 2023 · 2 months · monthly snapshot~Jul 2023 – ~Oct 2023 · 3 months · monthly snapshot~Oct 2023 – ~Jan 2024 · 3 months · monthly snapshot~Jan 2024 – ~May 2024 · 4 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

24 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. May 2024 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2024 — May 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 19 earlier versions

  1. Oct 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Jul 2023 — Oct 2023 [monthly]

    Active Not Recruiting PHASE2

  3. May 2023 — Jul 2023 [monthly]

    Active Not Recruiting PHASE2

  4. Apr 2023 — May 2023 [monthly]

    Active Not Recruiting PHASE2

  5. Mar 2023 — Apr 2023 [monthly]

    Active Not Recruiting PHASE2

  6. Feb 2023 — Mar 2023 [monthly]

    Active Not Recruiting PHASE2

  7. Jan 2023 — Feb 2023 [monthly]

    Active Not Recruiting PHASE2

  8. May 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE2

  9. Jan 2022 — May 2022 [monthly]

    Active Not Recruiting PHASE2

  10. Oct 2021 — Jan 2022 [monthly]

    Active Not Recruiting PHASE2

  11. Jan 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE2

  12. Dec 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  13. May 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE2

  14. Aug 2019 — May 2020 [monthly]

    Active Not Recruiting PHASE2

  15. Aug 2018 — Aug 2019 [monthly]

    Active Not Recruiting PHASE2

  16. Jun 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE2

  17. May 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  18. Feb 2017 — May 2017 [monthly]

    Active Not Recruiting PHASE2

  19. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Beat NB Cancer Foundation
  • Because of Ezra
  • Giselle Sholler
  • K C Pharmaceuticals Inc.
Data source: Milton S. Hershey Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Austin, United States , Boston, United States , Charleston, United States , Charlotte, United States , Columbus, United States , Dallas, United States , Grand Rapids, United States , Hartford, United States , Hershey, United States , Honolulu, United States and 12 more locations